Page 6,387«..1020..6,3866,3876,3886,389..6,4006,410..»

Cell Therapeutics’ Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms) Inhibitor CT-1578 Demonstrates Ability to …

Posted: Published on October 15th, 2012

SEATTLE, Oct. 15, 2012 /PRNewswire/ --Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CT-1578's (previously known as SB-1578) unique kinase spectrum that selectively inhibits JAK2 over JAK1 or JAK3, coupled with its inhibition of FLT-3 and c-Fms, produced potency in not only preventing the development of rheumatoid arthritis ("RA"), but also in its treatment and reversal of bone and joint destruction after the onset of RA in preclinical models according to results published in the October 15, 2012 issue of the Journal of Immunology. The authors concluded that CT-1578's selective inhibition of JAK2, FLT-3 and c-Fms, which are the three kinases that are critical to the pathogenesis of RA, is unprecedented in the current stable of kinase inhibitors. "These results support the hypothesis that inhibition of JAK1 and JAK3 is not mandatory for therapeutic benefit in RA," noted Jack W. Singer, M.D., EVP Global Medical Affairs and Translational Medicine at CTI. "The results demonstrate that CT-1578's unique kinase spectrum not only blocks the inflammatory response, but prevents the infiltration of macrophages and neutrophils into affected joints, while inhibiting antigen presenting dendritic cells and the autoimmune component of the disease. These attributes resulted in prevention of joint synovial … Continue reading

Posted in Cell Medicine | Comments Off on Cell Therapeutics’ Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms) Inhibitor CT-1578 Demonstrates Ability to …

Cell Therapeutics' Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms) Inhibitor CT-1578 Demonstrates Ability to …

Posted: Published on October 15th, 2012

SEATTLE, Oct. 15, 2012 /PRNewswire/ --Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CT-1578's (previously known as SB-1578) unique kinase spectrum that selectively inhibits JAK2 over JAK1 or JAK3, coupled with its inhibition of FLT-3 and c-Fms, produced potency in not only preventing the development of rheumatoid arthritis ("RA"), but also in its treatment and reversal of bone and joint destruction after the onset of RA in preclinical models according to results published in the October 15, 2012 issue of the Journal of Immunology. The authors concluded that CT-1578's selective inhibition of JAK2, FLT-3 and c-Fms, which are the three kinases that are critical to the pathogenesis of RA, is unprecedented in the current stable of kinase inhibitors. "These results support the hypothesis that inhibition of JAK1 and JAK3 is not mandatory for therapeutic benefit in RA," noted Jack W. Singer, M.D., EVP Global Medical Affairs and Translational Medicine at CTI. "The results demonstrate that CT-1578's unique kinase spectrum not only blocks the inflammatory response, but prevents the infiltration of macrophages and neutrophils into affected joints, while inhibiting antigen presenting dendritic cells and the autoimmune component of the disease. These attributes resulted in prevention of joint synovial … Continue reading

Posted in Cell Medicine | Comments Off on Cell Therapeutics' Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms) Inhibitor CT-1578 Demonstrates Ability to …

State licensing hearing for Bonita Springs stem cell doctor to begin Tuesday

Posted: Published on October 15th, 2012

The Grekos hearing is scheduled to begin at 9 a.m. Tuesday in the Martin Luther King, Jr. Administration Building, room 1-140A, 5775 Osceola Trail, Naples. It is scheduled for four days. Photo by Allie Garza Zannos Grekos BONITA SPRINGS Bonita Springs physician Zannos Grekos, whose license is in jeopardy for controversial stem cell therapy, is getting his day before a judge. Barring a last-minute delay or settlement, an administrative hearing is scheduled to begin Tuesday in Naples for the 47-year-old. He is fighting to get his license back in good standing from a suspension order, while the state Department of Health is pursuing more discipline and potentially revocation of his license. Trained as a cardiologist, he's been licensed in Florida since 1996. The trial-like proceeding, without a jury, is scheduled for four days before an administrative law judge. The proceeding is open to the public. The case against Grekos has garnered considerable media attention, including CNN and inquiries from European media. A Texas father, Jimmy Bell, will be tracking what happens. Last year, he paid $57,000 upfront for his 5-year-old son, Jason, to undergo stem cell therapy to fight pulmonary hypertension. Despite pleas that his boy was weakening by the … Continue reading

Posted in Cell Therapy | Comments Off on State licensing hearing for Bonita Springs stem cell doctor to begin Tuesday

Abbott Labs rises on hepatitis C drug data

Posted: Published on October 15th, 2012

NEW YORK (AP) Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease. Patients who took a three-drug regimen and the drugs Ritonavir and ribavirin had undetectable virus levels after 12 weeks of treatment. The North Chicago, Ill., company says it observed a 93 percent cure rate in a group of patients who were not helped by other treatments. Patients in the trial had genotype 1 hepatitis C, which is the most common type in the Western world and the hardest to treat. The regimen did not include interferon, a standard component of hepatitis C therapy that causes flu-like side effects that can last for months. The study included 77 patients who hadn't been treated before and 41 patients who were not helped by other treatments. Abbott shares rose $2.27, or 3.3 percent, to $71.55 in afternoon trading. The stock has been trading around all-time highs and peaked at $71.99 earlier in the session. Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the U.S. Analysts say the … Continue reading

Posted in Drug Side Effects | Comments Off on Abbott Labs rises on hepatitis C drug data

Nektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at …

Posted: Published on October 15th, 2012

SAN FRANCISCO, Oct. 15, 2012 /PRNewswire/ --Nektar Therapeutics (NKTR) today announced that preclinical data for NKTR-171, a new investigational drug candidate to treat neuropathic pain, was presented at the 41st Annual Meeting of the Society for Neuroscience: Neuroscience 2012. NKTR-171 is a novel sodium channel blocker designed to act in the periphery in order to treat neuropathic pain while avoiding the serious central nervous system (CNS) side effects associated with current therapies, including anti-epileptic and anti-convulsant medications, such as gabapentinoids. Neuropathic pain, also known as nerve pain, is a type of chronic pain that occurs when nerves become injured or damaged by systemic disease, infections, autoimmune disease, or physical trauma due to toxins or injuries. It is estimated to effect more than 20 million people in the U.S. alone.1 "Sodium channels have long been known to play a significant role in the changes in neuronal excitability that lead to neuropathic pain," said Stephen Doberstein, Ph.D., Senior Vice President and Chief Scientific Officer of Nektar Therapeutics. "We are extremely pleased that NKTR-171 exhibits effective analgesia in multiple neuropathic pain models without generating the CNS side effects observed with current therapies used to treat neuropathic pain. We look forward to continuing to … Continue reading

Posted in Drug Side Effects | Comments Off on Nektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at …

Community Briefs

Posted: Published on October 15th, 2012

Freedom From Chemical Dependency workshop As part of Colorado Rocky Mountain School's ongoing commitment to prevention and wellness, we have once again invited a faculty member from Freedom from Chemical Dependency Educational Services (FCD) to join our community and facilitate a parent workshop that is open to the public. Join us at 7 p.m. Thursday, Oct. 18, at CRMS for this workshop that will offer parents support and guidance in helping their children enjoy a drug-free adolescence. Among the topics discussed will be: Effective ways to communicate with your child about drugs and drug use. Up-to-date facts about current drug use and trends. What to say about your own experiences with alcohol and/or drug experimentation. How to spot early warning signs of trouble and effective ways to respond. This series is free to the public and will cover employer responsibility of how to verify new hire documentation along with other subjects. RSVP to the Glenwood Springs Workforce Centers at 970-945-8638 or to Rifle at 970-625-9716 by Monday, Oct. 15. Applications are available at Colorado Mountain College student services/financial aid offices at Rifle, Glenwood Springs, Spring Valley and Carbondale. Email kygirlncokid@aol.com to receive an application via email. Scholarship application deadline is … Continue reading

Posted in Drug Dependency | Comments Off on Community Briefs

FDA Currently Considering Faster Pathway for Drugs Deemed to Offer Societal Benefit

Posted: Published on October 15th, 2012

NEW YORK, NY--(Marketwire - Oct 15, 2012) - The Food and Drug Administration Commissioner Margaret Hamburg has told scientific advisers that the FDA is considering a faster pathway for obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on MannKind Corporation ( NASDAQ : MNKD ) and Dendreon Corporation ( NASDAQ : DNDN ). Access to the full company reports can be found at: http://www.ParagonReport.com/MNKD http://www.ParagonReport.com/DNDN Under the new pathway the FDA would allow developers of such drugs to conduct smaller, faster clinical trials, and provide a "special medical use" label which would allow doctors to administer drugs to patients with critical needs. Hamburg has said that the FDA needs to take into account the needs of people with deadly or debilitating diseases that may be willing to take on the risks of unproven drugs. "A pathway that would allow products to come to market faster but would ensure they were used only in patients where there was an applicable risk-benefit situation would be good," said Pew Health Group's Allan Coukell, deputy director of medical programs. "It would be good for developers, for … Continue reading

Posted in Drugs | Comments Off on FDA Currently Considering Faster Pathway for Drugs Deemed to Offer Societal Benefit

New drugs deal to save 400m euro

Posted: Published on October 15th, 2012

More than 400 million euro is expected to be shaved off the State's bill for medications over the next three years. Health Minister James Reilly said the new deal was struck during intensive negotiations involving the Irish Pharmaceutical Healthcare Association (IPHA) and the Health Service Executive. The scheme will result in significant reductions for patients in the cost of drugs, as well as lower the drugs bill to the State and ease financial pressure on the health service. The IPHA said the new supply agreement will ensure new medicines are made available to Irish patients. David Gallagher, outgoing president who led the negotiations, said: "Medicines are a key pillar of any advanced health system and medical innovation has extended life expectancy through reducing illness and death. "Many patients are in need of new advanced medicines in areas such as Alzheimer's disease, arthritis, cancer, stroke prevention, multiple sclerosis and cystic fibrosis." The State pays out some 2 billion euro on drugs each year - with Dr Reilly heavily criticised for health spending overruns. And his former junior minister, Roisin Shortall, whose shock resignation rocked the coalition Government last week, attacked Dr Reilly for not managing the HSE budget, in particular his … Continue reading

Posted in Drugs | Comments Off on New drugs deal to save 400m euro

AUDIO: Schools 'must prioritise drugs education'

Posted: Published on October 15th, 2012

It should no longer be a criminal offence to use small amounts of drugs, the UK Drug Policy Commission has concluded after a six-year study of Britain's drugs laws. It was funded by an independent charity and is composed of some well-respected figures from medicine and the police. Their report says existing drugs policies struggle to make an impact and in some cases may make the problem worse. The commission's chief executive Roger Howard told the Today programme: "We need to base future drug policy on what works, on evidence, and we're calling for a new body to be set up to be able to promote that." Independent drugs expert Sarah Graham disagrees with some of the report's findings and said: "I'm specifically interested in drugs education in schools. When I work with young people they tell me they don't get enough drugs education. "I think we need to be prioritising drugs education because young people are being educated on the streets, by papers, by pop stars, and we need to make sure the information they're getting is scientifically backed up." Get in touch with Today via email , Twitter or Facebook or text us on 84844. Read more from … Continue reading

Posted in Drugs | Comments Off on AUDIO: Schools 'must prioritise drugs education'

Drugs Experts Call For Major Policy Review

Posted: Published on October 15th, 2012

Using illegal drugs is like gambling or eating junk food, the independent body that analyses drug laws has claimed as it called for a review of the Government's approach. The final report by the UK Drug Policy Commission (UKDPC) pointed out that there are "some moderately selfish or risky behaviours that free societies accept will occur and seek to limit ... rather than to prevent entirely". Its six-year study found much of the 3bn the UK spends annually on tackling illicit drugs is not based on evidence. It said until the Government pursues policies based on what works, it would continue to waste public money and damage lives. Calling for a "wholesale review" of drugs laws and the classification system, it said possession of small amounts of drugs for personal use should be made a civil offence instead of a criminal offence. Some 42,000 people in England and Wales are sentenced each year for the possession of drugs, with about 160,000 people given cannabis warnings, the report added. For cannabis, there was also an argument that amending the law relating to the growing of it, at least for personal use, might go some way to undermining the commercialisation of production, … Continue reading

Posted in Drugs | Comments Off on Drugs Experts Call For Major Policy Review

Page 6,387«..1020..6,3866,3876,3886,389..6,4006,410..»